Program Agenda

5:00 pm **Registration**

5:30 pm **Welcome and Introductions**

Daniel A. Haber, MD, PhD
Director, Mass General Cancer Center

Henri A. Termeer
Former Chairman, President and CEO, Genzyme Corporation

Keith Flaherty, MD
Director, Henri and Belinda Termeer Center for Targeted Therapies, Mass General Cancer Center

Panel Discussion
Precision Medicine 2.0: Conquering Heterogeneity and Therapeutic Resistance in Cancer

Moderator

Dejan Juric, MD
Director of Translational Research, Henri and Belinda Termeer Center for Targeted Therapies, Mass General Cancer Center

Panelists

Priscilla Brastianos, MD
Director, Brain Metastasis Program, Massachusetts General Hospital

Douglas A. Lauffenburger, PhD
Professor, Biological Engineering Division, Department of Chemical Engineering, and Department of Biology
Massachusetts Institute of Technology

Jonathan Pachter, PhD
Chief Scientific Officer, Verastem

Phil Stephens, PhD
Chief Scientific Officer, Foundation Medicine

6:30 pm **Interactive discussion with audience**

7:30 pm **Cocktail reception**

Please respond by email to Erin O'Leary:
eoleary2@partners.org.

Directions to the Paul S. Russell MD Museum of Medical History and Innovation

Mass General Parking Garages Parking will be validated *(for up to 4 hours)*

From the North or South

- Via I-93 or U.S.-1 take the Storrow Drive exit.
- Take the Government Center exit (on left).
- At second traffic light, take left onto Cambridge Street (follow signs to Downtown and Government Center).
- Keep right at the fork, then continue straight.
- Once underneath the T station overpass, take a slight left onto Cambridge Street.
- At the first set of lights, take a left into the main entrance of Massachusetts General Hospital. The entrance to the museum will be directly on your left.
- Park in the Fruit Street Garage, Parkman Street Garage or Yawkey Center Garage.

From the West

- Via the Massachusetts Turnpike, take Exit 18 towards Brighton/ Cambridge.
- Bear right after the toll booth (follow signs for Cambridge/ Somerville).
- Turn right onto Storrow Drive eastbound to Downtown Boston.
- Take the Government Center exit.
- Proceed through traffic light onto Cambridge Street, towards Government Center.
- At the first set of lights, take a left into the main entrance of Massachusetts General Hospital. The entrance to the museum will be directly on your left.
- Park in the Fruit Street Garage, Parkman Street Garage or Yawkey Center Garage.

MASSACHUSETTS GENERAL HOSPITAL
CANCER CENTER

MASSACHUSETTS GENERAL HOSPITAL
CANCER CENTER

The Henri and Belinda Termeer Center for Targeted Therapies Presents a Roundtable Panel Discussion on:

Precision Medicine 2.0: Conquering Heterogeneity and Therapeutic Resistance in Cancer

Tuesday, January 17, 2017 • 5:00 pm – 8:30 pm
The Paul S. Russell MD Museum of Medical History and Innovation
Massachusetts General Hospital
2 North Grove Street • Boston, MA 02114

Hosts

Daniel A. Haber, MD, PhD

Director, Mass General Cancer Center

Dr. Haber is Director of the Mass General Cancer Center and the Isselbacher/Schwartz Professor of Oncology at Harvard Medical School. His laboratory focuses on cancer genetics and is broadly known for discoveries that have improved the treatment of cancers such as non-small cell lung cancer, breast cancer and Wilms tumor, as well as for innovation in cancer diagnostics.

Henri A. Termeer

Former Chairman, President and CEO, Genzyme Corporation

Mr. Termeer served as Chairman, President and Chief Executive Officer of Genzyme Corporation for nearly three decades. Under his leadership, Genzyme grew from a modest entrepreneurial venture into one of the world's leading biotechnology companies. Mr. Termeer resigned from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi. He is a member of the board at both Mass General Hospital and Partners HealthCare.

Keith T. Flaherty, MD

Dr. Flaherty is a Professor of Medicine at Harvard Medical School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital, and Director of the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center. He is also the Deputy Chair for Biomarker Sciences and the Chair of the Developmental Therapeutics Committee in the Eastern Cooperative Oncology Group. Dr. Flaherty has served as principal investigator for numerous first-in-human clinical trials with novel, targeted therapies, including the first in-human trials of the first prospectively developed selective BRAF inhibitors for metastatic melanoma.

Panelists

Dejan Juric, MD • moderator

Dr. Juric is physician-scientist involved in early drug development of targeted cancer therapeutics in metastatic breast cancer and other advanced solid malignancies. He is primarily focused on first-in-human studies of isoform selective PI3K inhibitors in genetically predefined populations of patients. He is also interested in the identification of genetic alterations and cell signaling networks which confer resistance or modulate the action of anti-HER2 agents and selective PI3K-alpha inhibitors in established cell lines and patient-derived tumor models, with the aim to develop new combinatorial treatment strategies for patients with advanced cancers driven by HER2 amplifications and/or PI3K-pathway alterations.

Priscilla Brastianos, MD

Dr. Brastianos' research focuses on understanding the molecular mechanisms that drive brain tumors and metastasis. She is currently focused on understanding the genomic evolution of brain metastases. Along with a team of collaborators to study the molecular pathogenesis of brain metastases, she has created an extensive tissue bank of matched brain metastases and primary tumors and is currently elucidating their molecular evolution at the Broad Institute of Harvard and MIT. Her pioneering work in brain metastases demonstrates that brain metastases have divergent evolution, and harbor clinically significant drivers that are distinct from clinically sampled primary tumors.

Phil Stephens, PhD

Dr. Stephens brings more than a decade of experience in cancer genomics to Foundation Medicine. He is a world-renowned expert in next-generation sequencing and cancer genome analysis and has authored numerous publications. Prior to joining Foundation Medicine, Dr. Stephens held various research positions during his 11-year tenure with the Cancer Genome Project at the Wellcome Trust Sanger Institute. During this time, Dr. Stephens was a member of the team that sequenced the first two comprehensive melanoma and lung cancer genomes, and was co-lead author in the discovery of BRAF in melanoma and ERBB2 in lung cancer.

Douglas A. Lauffenburger, PhD

Dr. Lauffenburger is the Ford Professor of Bioengineering and (founding) Head of the Department of Biological Engineering at MIT. Professor Lauffenburger also holds appointments in the Department of Biology and the Department of Chemical Engineering, is a member of the Center for Biomedical Engineering, Center for Gynepathology Research, and Koch Institute for Integrative Cancer Research. A central focus of his research program is in receptor-mediated cell communication and intracellular signal transduction important in pathophysiology with application to drug discovery and development, with emphasis on development of predictive computational models derived from quantitative experimental studies. He has served as a consultant or scientific advisory board member for a number of bio/pharma companies.

Jonathan Pachter, PhD

Dr. Pachter brings over 25 years of experience in leading discovery and translational research for small molecule and monoclonal antibody anti-cancer therapeutics. He was previously Head of Cancer Biology at OSI Pharmaceuticals where his team was responsible for development of models of tumor cell EMT and discovery of drugs disrupting this process. At OSI he advanced five small molecules into development for treatment of cancer, including OSI-906 – a selective IGF-1R/ insulin receptor kinase inhibitor which progressed to phase III clinical trials and OSI-027 – a selective mTOR kinase inhibitor. Prior to OSI, Dr. Pachter held positions at Schering-Plough where he advanced three agents into development including the monoclonal antibody robatumumab which advanced to phase II clinical evaluation in cancer patients. Dr. Pachter also made key contributions to the regulatory approval of temozolomide for treatment of glioblastoma.